Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. - Wikidata - wikimedia - TriplyDB

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q37345347

about

Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Recent applications of chemosensitivity tests for colorectal cancer treatment Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancer Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy Identification of risk factors for recurrence in high-risk stage II colon cancer Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Building personalized treatment plans for early-stage colorectal cancer patients.Biomarker-based selection of therapy for colorectal cancer.Pharmacogenetics of chemotherapy efficacy in breast cancer.XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis.

P2860

Q26749012-91F7689D-F30E-4269-A81E-917F4B164579 Q26851075-064D5A0C-A532-42EB-880D-F8CB52772DB9 Q28554294-6E273A4E-A2AA-405A-80AF-63CBEECDBEC0 Q33634975-4F4E4781-3158-4862-86F8-9F6B3545B18D Q34112730-C8E31236-F73C-449B-B28B-933178A40F9D Q34653433-FA8FFDD0-6130-49E8-9D9B-83DCC0345FED Q34676948-AF60377C-D052-44F3-A004-173782890C16 Q34694410-39D26A2E-D914-4DB3-B0B4-BC198F311510 Q35109800-A4A58416-582A-40BC-ABD5-3C16F35C3DF6 Q35194655-4EC449D7-3220-4674-B914-B916822FB91C Q35224176-C5B5B4F8-4B86-49D7-A2B9-9DAE09C3C832 Q35929617-A5F56AD3-5978-457C-8398-E7ACCA2CE8EC Q36117701-E8F69DE9-7E57-4429-BC03-D806CB7F6B08 Q36385034-B64D1D0C-B3EA-4E03-8B88-B9688A5A3C1F Q36467960-4E576C1D-7109-4E3F-A688-F9FE8E1CB0AF Q37039153-6DCAB1FF-CCAA-4F91-8169-6BFCD953971E Q37044768-A5F20789-9A0E-4C85-9DCC-CAE8816243C8 Q37165280-8333FEAB-7E89-4B8A-A3F6-818EF03DF74C Q37206438-E09B719F-02D3-41DB-9816-58C8EC5A1263 Q37471631-2E48B6CA-6420-45BF-94C7-6F6E0B3000DC Q37706705-C2432D0D-35BB-40C9-8B70-25CEE0C93CDD Q37886995-24A99B6A-B064-4734-A54C-3926982EC33D Q38003703-47FB1A2E-D05D-4EE1-B703-1537F6F6DCEE Q38072637-C638F602-0FB6-4976-8723-B91E48916E14 Q38162285-F7D421DE-9443-490F-A493-3EFD73B39AE2 Q38835268-127FC53E-4C46-4B38-B3DA-54D2654EB396 Q39307013-75761CA3-A892-4AF9-934F-4C9E947F8B4E Q39566084-D7F61359-A3B3-4AAF-A194-C3B62112813A Q43986380-FB2138A1-024B-46DF-A3EE-B502309EF7E5 Q44661317-C162A993-36B9-4A38-AC27-9E8E3BE160A1 Q48310481-3F0C72A5-78B6-4E48-8B29-986DB681D82C Q54374974-F75DCCB4-6412-4D24-860D-AD8122EE04EF

P2860

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

http://www.wikidata.org/entity/Q37345347

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Molecular markers of response ...... metastatic colorectal cancer.

@en

Molecular markers of response ...... metastatic colorectal cancer.

@nl

type

label

Molecular markers of response ...... metastatic colorectal cancer.

@en

Molecular markers of response ...... metastatic colorectal cancer.

@nl

prefLabel

Molecular markers of response ...... metastatic colorectal cancer.

@en

Molecular markers of response ...... metastatic colorectal cancer.

@nl

P1433

Q37345347-BFC1DDDA-AC2D-40F3-B36A-A9B3A09150C4

P1476

Q37345347-406F3BB9-571A-4A6B-A78F-B80F1FE51A42

P2093

Q37345347-4E61D6C3-5AE4-4ACF-A622-C02C78CC3960

Q37345347-53E5959F-670B-49A0-A741-AB013C3F4836

Q37345347-9EF0159B-438C-430C-A2AA-0EB1756FD8D0

Q37345347-9FF68E7C-4C89-4E30-9155-62FE17A961EF

Q37345347-CEB4CC69-D20E-46E6-BE9C-04CC80FA9B43

Q37345347-DA87D05B-A763-488C-9AA8-0275518366FD

P2860

Q37345347-09AAE373-AF2A-4FFC-A65E-5D446FD4AC50

Q37345347-206778A2-36B0-4E2B-A3FC-3F6380C9CFA3

Q37345347-2AA5F851-8C2E-475A-B329-D5952E79242C

Q37345347-2D9F4095-3CAE-48D5-AD51-B6A792CF8B13

Q37345347-2E7F1CC5-EB4A-46F6-BCA8-F186DA55C053

Q37345347-2FF2003B-A8EB-4765-8E25-165BA8698366

Q37345347-3915A8B2-0473-4594-A3DA-E13758761D9E

Q37345347-3B95F746-3930-4F8C-B6EB-F51AB48A8EEA

Q37345347-4169A14F-0C24-49E7-9578-FAA99A4B578D

Q37345347-47B8AEF1-D33F-4331-AEFF-050366026FEA

P2888

Q37345347-1FE46BA1-C070-4FFD-BA62-03F99BB8DFC2

P304

Q37345347-E66A2113-72E6-4502-8238-0BC8BB6E7208

P31

Q37345347-56C649F1-4687-4149-8961-A3ACE814B026

P356

Q37345347-309C1D83-A6B2-4228-BA6C-AC715863DE5B

P407

Q37345347-E2297B01-FFA3-4E72-B6F4-961D6AE73778

P433

Q37345347-297E9761-812D-4F30-974E-7A669E41EDD9

P478

Q37345347-A48BD91F-C97C-4096-9E48-9D9C84FE5F8E

P50

Q37345347-8177FE5A-34C0-4B3A-A7BE-7A1E5DBD0716

Q37345347-D8482514-F105-4ED1-B46C-D24AE07460FD

P577

Q37345347-47C8AF77-1DD9-4CE5-98C5-9872CCC61198

P5875

Q37345347-B40490E5-C37D-47F1-91EC-50A10E123707

P698

Q37345347-CBF7CBE8-ED56-4A67-A57C-289559069FFF

P921

Q37345347-8580ABFB-2A0C-448D-B715-A0742633DCE9

Q37345347-FEA76DE4-B125-4B6A-862E-31A8C2C58BF7

P932

Q37345347-7CE1659B-2A07-4051-AA48-3C5B60B0180F

P356

P1433

British Journal of Cancer

P1476

Molecular markers of response ...... n metastatic colorectal cancer

@en

P2093

B Iacopetta

http://www.w3.org/2001/XMLSchema#string

D Goldstein

http://www.w3.org/2001/XMLSchema#string

M Michael

http://www.w3.org/2001/XMLSchema#string

P Mitchell

http://www.w3.org/2001/XMLSchema#string

S J Clarke

http://www.w3.org/2001/XMLSchema#string

W Chua

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Reporting results of cancer treatment

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

P2888

P304

998-1004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605239

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Haryana Dhillon

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733760

http://www.w3.org/2001/XMLSchema#string

P698

19672255

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2743363

http://www.w3.org/2001/XMLSchema#string